A Personalized Approach to Radiation Therapy


It may soon be possible to get rid of the “one-size-fits-all” approach when it comes to radiation therapy.

It may soon be possible to get rid of the “one-size-fits-all” approach when it comes to radiation therapy. Investigators at the Moffitt Cancer Center are reporting on a new approach that can individualize a cancer patient’s radiotherapy dose to their tumor radiosensitivity. They have just published a study in The Lancet Oncology suggesting that this new approach could benefit patients in many ways, including its use to design genomically-guided clinical trials in radiation oncology.

Cancer is a highly heterogeneous disease and patients can achieve better outcomes if their treatments are tailored to the specific biology of their tumors. However, despite the growth of precision medicine, little progress has been made in personalizing radiation therapy. Now, researchers believe that precision medicine has a role in radiation therapy and it can be used to improve patient outcomes and reduce toxicities. 

Investigators conducted a study in which they assessed whether a patient-specific molecular signature of radiation sensitivity could be used to identify the optimum radiotherapy dose.

Previously, Moffitt researchers developed a gene expression-based radiosensitivity index (RSI). They found it was able to predict tumor sensitivity to radiation therapy based on the expression of 10 specific genes. The RSI accurately predicted clinical outcomes in many different cancer patients treated with radiation, including breast, head and neck, glioblastoma, pancreas, and metastatic colorectal cancer patients.

In this current study, the researchers used the RSI to develop a genomics model called the genomic-adjusted radiation dose (GARD) that was able to predict the therapeutic effect for radiotherapy. They demonstrate that GARD values were consistent with the clinical heterogeneity of radiotherapy therapeutic benefit. For example, gliomas and sarcomas are known to be resistant to radiation and they had the lowest GARD values. Cervical and head and neck cancers, which are known to be sensitive and radiocurable, had the highest GARD values.

“With multidisciplinary care becoming standard for the majority of cancer patients, it is critical that precision medicine is expanded beyond drug therapy,” said Louis Harrison, MD, who is chair of Moffitt’s Radiation Oncology Department in Tampa, Fla. “The GARD model provides the first opportunity to genomically-inform radiation dose and is a safe and feasible approach to precision radiation oncology.”

The study confirmed that the GARD model could predict the clinical outcomes of 263 breast cancer patients who were treated with radiation therapy and surgery. The model could also predict the outcomes of additional sets of patients, including glioblastoma, lung, and pancreatic cancer patients.

The investigators hypothesize that GARD could be used to customize a patient’s radiation dose so that they are receiving the optimal dose to achieve the greatest benefit with the least amount of toxicity.


Related Videos
Hypofractionated radiotherapy yields less financial toxicity than conventionally fractionated radiotherapy in patients with breast cancer who have undergone reconstruction following mastectomy.
Those with breast cancer who have undergone implant-based reconstruction following mastectomy have similar outcomes with hypofractionated vs conventionally fractionated radiotherapy.
An expert from Dana-Farber Cancer Institute indicates that urologists should refer patients with prostate cancer who present with multiple high-risk factors at surgery to a radiation and medical oncologist.
Fifteen-year results of the ProtecT prostate cancer trial may support the findings of the study’s 10-year follow-up data, according to an expert from Dana-Farber Cancer Institute.
Increasing age, higher Gleason scores, and higher pathologic stages are predictors of mortality in patients with prostate cancer, according to an expert from Dana-Farber Cancer Institute.
Clinical trials highlight benefits, including radiographic progression-free survival following treatment with radioligand 177Lu-PSMA-617 in pretreated patients with metastatic castration-resistant prostate cancer.
Early data from ongoing clinical trials suggest the potential safety and efficacy of novel radium-223 combinations as treatment for metastatic castration-resistant prostate cancer.
Current clinical trials look to assess 177Lu-PSMA-617 in combination with other therapies including androgen deprivation therapy and docetaxel.
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
Related Content